Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide

You'll have to have your doctor get this so YOU can analyze the efficacy and safety of tPA for stroke use. Then see if your stroke hospital is doing anything at all to address the atrocious failure rate of 88%  in getting to complete recovery using tPA. All this should be widely and freely published on every stroke association website in bold flashing letters. tPA is mostly a complete failure. Beware all who enter here after a stroke.
http://www.ncbi.nlm.nih.gov/pubmed/27363696

Demaerschalk BM^1,2.

Author information

Abstract

Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.

KEYWORDS:

Alteplase; Food and Drug Administration; Guidelines; Ischemic stroke; Tissue plasminogen activator

PMID:

27363696

DOI:

10.1007/s11883-016-0602-5

[PubMed - in process]